Promising drug cocktail targets Hard-to-Treat head and neck cancer
NCT ID NCT07088211
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls 39 adults whose tumors have specific markers (Trop2 and CPS). The goal is to see how many patients respond to the treatment and how long they live without the cancer growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan and toripalimab
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with recurrent or metastatic head and neck cancer that has specific markers.
- What could go wrong
- This is a small, early-phase trial with only 39 participants and no control group. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200011, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tackle recurrent head and neck cancer
- New drug combo targets Hard-to-Treat head and neck cancers
- New drug combo targets Hard-to-Treat head and neck cancer
- New hope for head and neck cancer: drug combo shows promise after standard treatment fails
- Promising combo therapy for head and neck cancer hits early snag
- Gut health boost may tame immunotherapy side effects in head and neck cancer